The effects of S-allylmercaptocaptopril, the synthetic product of allicin and captopril, on cardiovascular risk factors associated with the metabolic syndrome

详细信息    查看全文

• 作者：Mor Oron-Herman ; Talma Rosenthal ; David Mirelman ; Talia Miron ; Aharon Rabinkov ; Meir Wilchek and Ben-Ami Sela
• 关键词：Metabolic syndrome ; Cardiovascular risk factors ; Hypertension ; Insulin resistance ; Triglycerides ; Homocysteine ; Allicin ; Captopril
• 刊名：Atherosclerosis
• 出版年：2005
• 出版时间：December 2005
• 年：2005
• 卷：183
• 期：2
• 页码：238-243
• 全文大小：203 K

文摘

Pure allicin, prepared biosynthetically by reacting synthetic alliin with an immobilized alliinase enzyme, is known to possess cardioprotective effects. However, in its pure form, allicin is pharmacologically unstable. S-allylmercaptocaptopril (CPSSA) is a new stable synthetic compound produced by chemical reaction between allicin and the angiotensin converting enzyme inhibitor captopril. Using the fructose-induced metabolic syndrome rat model we studied the effects of short-term treatment with two doses of CPSSA on cardiovascular risk factors associated with the metabolic syndrome, in comparison to the effects of allicin and captopril separately. Allicin (8 mg/(kg day)) significantly reduced insulin, triglycerides, and homocysteine concentrations, and had a slight effect on SBP. Captopril (50 mg/(kg day)) only improved blood pressure and homocysteine. Treatment with low dose of CPSSA (5 mg/(kg day)) lowered SBP but did not improve any other measured parameter, while treatment with a higher dose (50 mg/(kg day)) significantly decreased blood pressure, triglycerides, and homocysteine concentrations. We conclude that the combined molecule CPSSA integrates the anti-hypertensive, lipid-lowering, and homocysteine-reducing effects of both allicin and captopril, making it a potential cardiovascular protective agent.